Is the GSK share price worth buying?

GlaxoSmithKline plc (LON: GSK) has posted some good results. But is it worth investing in?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Being a shareholder in GlaxoSmithKline (LSE: GSK) can’t be boring. Over the past year, the stock has bounced between 1,400p a share and 1,700p a share. Over a longer time scale, the situation is the same, with the stock frequently oscillating between 1,300p and 1,700p over the last five years. Right now, it is trading near the top of this range. Is there reason to believe that it might continue to rise? Let’s dig deeper.

Recent developments 

First things first. In a recent trading update for the second quarter, Glaxo posted total revenues of £7.8bn, of which £4.3bn came from pharmaceuticals. This was good for a 7% total revenue increase year-on-year. This allowed management to improve its guidance for 2019 to a 3% to 5% decrease from the previous year. This doesn’t sound that great, but it should be viewed in the context of the 5% to 9% drop that had previously been guided for. 

The best results came from the pharmaceutical giant’s vaccines segment. Here, sales increased by a whopping 26%, no mean feat considering that total revenue for the division came in at £1.6bn. Management also confirmed that Glaxo’s dividend will be maintained at 80p a share (per year). 

A deep pipeline

As mentioned, Glaxo’s biggest gains recently have been in vaccines. In particular, its shingles vaccine Shingrix has been performing extremely well, bringing in £386m in revenue in the second quarter. This was due to high levels of demand in the US, as well as Germany and Canada. Earlier this year, Glaxo received approval from Chinese authorities to market Shingrix in the country. CEO Emma Walmsley should be confident that Shingrix will continue to be a driver of growth for the company. Furthermore, Glaxo boasts a very busy pipeline of promising new drugs, ranging from HIV treatments to respiratory medications. 

That said, Glaxo has had to contend with a serious headwind. It recently lost exclusivity for Advair, the company’s blockbuster asthma treatment. To give you a measure of just how big this is: Advair is the fourth most-prescribed medication in the USA over the last quarter century. When pharmaceutical rival Mylan released a generic competitor to Advair earlier this year (at a 70% discount), sales predictably collapsed. In the second quarter of 2019, US sales of Advair dropped 61%, bringing in just £105m, a far cry from the yearly haul of £6.75bn that the drug brought in at its peak in 2013.  Management has been preparing for this patent cliff for years and the market has been baking it into its earnings estimates, which is why Glaxo’s shares didn’t collapse following the release of those sales figures. However, it still leaves a void that needs to be filled. 

Is it worth the investment?

Glaxo currently trades at a P/E ratio of 15 and a dividend yield of 4.75%. To me, that seems somewhat expensive for a company that is still dealing with the loss of a once-in-a-century product. The P/E ratio and yield are essentially in line with the FTSE 100 average, which also does not give me a reason to get involved. True, pharmaceutical companies across the board are quite expensive. But luckily we don’t have to have positions in every single sector. All in all, I think that while Glaxo is well-positioned for the long-term, its current valuation does not justify an investment.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Stepan Lavrouk owns no shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Midnight is celebrated along the River Thames in London with a spectacular and colourful firework display.
Investing Articles

Prediction: this will be the FTSE 100’s next great stock!

This FTSE 250 stock has more than doubled in value during the past five years. Our writer thinks it could…

Read more »

Yellow number one sitting on blue background
Investing Articles

Billionaire Bill Ackman has just 1 magnificent AI stock in his FTSE 100-listed fund

Our writer takes a look at the only AI stock held in the portfolio of FTSE 100-listed Pershing Square Holdings.

Read more »

Stack of British pound coins falling on list of share prices
Investing Articles

2 penny stocks this Fool thinks could deliver phenomenal returns!

Penny stocks are a risky but exciting asset class to invest in, prone to wild volatility. Our writer thinks he's…

Read more »

Buffett at the BRK AGM
Investing Articles

I’ve just met Warren Buffett’s first rule of investing. Here are 3 ways I did it

Harvey Jones has surprised himself by living up to Warren Buffett's most important investment rule. But is his success down…

Read more »

Engineer Project Manager Talks With Scientist working on Computer
Investing Articles

Down 51% in 2024, is this UK growth stock a buy for my Stocks and Shares ISA?

Ben McPoland considers Oxford Nanopore Technologies (LSE:ONT), a UK growth stock that has plunged over 80% since going public in…

Read more »

Young Caucasian woman with pink her studying from her laptop screen
Investing Articles

These 3 growth stocks still look dirt cheap despite the FTSE hitting all-time highs

Harvey Jones is hunting for growth stocks that have missed out on the recent FTSE 100 rally and still look…

Read more »

Chalkboard representation of risk versus reward on a pair of scales
Investing Articles

Here’s how much I’d need to invest in UK income stocks to retire on £25k a year

Harvey Jones is building his retirement plans on a portfolio of top UK dividend income stocks. There are some great…

Read more »

Investing Articles

If I’d invested £5,000 in BT shares three months ago here’s what I’d have today

Harvey Jones keeps returning to BT shares, wondering whether he finally has the pluck to buy them. The cheaper they…

Read more »